Top News

• Biopharma sector got new strength
• 10,000 crore investment in the budget
• Job creation due to ‘Bio Pharma Shakti’ scheme

Bio-Pharma Budget 2026: Today Union Finance Minister Nirmala Sitharaman announced India’s financial year 2026-27 (Budget 2026-27) budget was presented. Bihar Deputy Chief Minister Samrat Chaudhary then described the budget and praised the Finance Minister and the Modi government. The presented budget was termed as historic and visionary budget. He particularly appreciated the ‘Bio Pharma Shakti’ programme, which would be a decisive step towards making India a global bio-pharma manufacturing hub. This belief was expressed.

“Building the largest economy in the world…”; Minister Mangalprabhat Lodha’s reaction on Union Budget 2026

The Finance Minister has proposed the ‘Bio Pharma Shakti’ scheme in the Budget 2026-27 to take the country’s biopharmaceutical sector to new heights. 10,000 crore will be spent on this over the next five years. Samrat Choudhary posted on X This huge investment will create a strong ecosystem for domestic production of biologicals and biosimilar medicines. Also, it will enable expensive drugs used to treat complex diseases to be manufactured in India at affordable prices. He expressed that belief.

Defense budget 2026: Record provision of 7.85 lakh crores for defense sector; 2.19 lakh crore for armaments

According to Deputy Chief Minister Samrat Chaudhary, the common people will benefit the most from this initiative. Biosimilar drugs are just as effective and safe as the original biological drug, but cost significantly less. This project will not only reduce India’s dependence on imports, but also make the country completely self-reliant in healthcare. Moreover, increased innovation and manufacturing in this sector will create thousands of high-skilled employment opportunities. He also said.

Also, the budget also fulfills Prime Minister Narendra Modi’s commitment to ‘Aatmanirbhar Bharat’ and he believes that the Rs 10,000 crore scheme will further strengthen India’s leadership position in the global pharmaceutical industry. This initiative will be a milestone in strengthening innovation capacity and ensuring affordable and accessible healthcare for the common man.